About US
Contact us
-
India's Cipla gets U.S. beachhead with $550M deal for 2 generics operationsIndia'sCiplamade its name in the west as a leader in challenging Big Pharma patents on expensive drugs in an effort to cut their prices in a country with a large need and little money. But it has lagg2015/9/7
-
UPDATED: AstraZeneca scores FDA nod for long-term Brilinta useAstraZeneca's ($AZN) blood thinnerBrilintais officially one step closer to living up to the $3.5 billion ambitions the British pharma laid out last February. TheFDAhas handed down an approval for long2015/9/6
-
India's Cipla gets U.S. beachhead with $550M deal for 2 generics operationsIndia'sCiplamade its name in the west as a leader in challenging Big Pharma patents on expensive drugs in an effort to cut their prices in a country with a large need and little money. But it has lagg2015/9/6
-
CFDA Vice Minister Wu Zhen meets Country Director of U.S. FDA China OfficeOn the morning of August 27, 2015, Wu Zhen, Vice Minister of China Food and Drug Administration (CFDA), met with the delegation led by S. Leigh Verbois, Country Director of U.S. FDA China Office. Both2015/9/2
-
Bernie Sanders proposes raft of legislation to combat rising drug pricesSen. Bernie Sanders, a longtime pharma watchdog, says he's rolling out legislation to stall drug price hikes. The presidential candidate's proposals include some previously failed measures--includingM2015/9/2
-
BMS, AbbVie nab 'breakthrough' tag for multiple myeloma-fighting antibodyA new drug for blood cancer from Bristol-Myers Squibb ($BMY) and AbbVie ($ABBV) is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.Report2015/9/2
-
No change in CV risk for ACS patients on Sanofi's LyxumiaLONDON--Back in June, researchers unveiled details of the ELIXA trial, which put Sanofi's Lyxumia in the clear as far as cardiovascular safety risks go. Now, a new analysis of the study shows that in2015/9/1
-
New hurdle for DPP-4 diabetes meds: FDA spotlights risk of 'disabling' joint painAs if last week'sJardiancenews wasn't enough to worry makers of DPP-4 diabetes drugs, theFDAhas now issued a warning that the class of meds might cause "severe and disabling" joint pain. The agency's2015/9/1
-
Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuseIt was attention-grabbing when California sued a handful of drugmakers, accusing them of lying about the safety of their high-powered painkillers and blaming them for an epidemic of prescription drug2015/8/31
-
Patient education 'useless' when it comes to Eliquis adherence: studyLONDON--Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant,Eliquis, atrial fibrillation patients posted adherence rates near 90%. And the icing2015/8/31